A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease
Stopped Several factors contributed to significant challenges in enrollment and led the Sponsor to discontinue the AMAG-FER-CKD-252 study as designed.
Conditions
- Iron Deficiency Anemia
- Nondialysis-dependent Chronic Kidney Disease
Interventions
- DRUG: Ferumoxytol
- DRUG: Oral Iron
Sponsor
AMAG Pharmaceuticals, Inc.